Answers are grounded in this paper and cite their sources.
Malaria remains a major public health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. The bifunctional dihydrofolate reductase-thymidylate synthase of Plasmodium falciparum (PfDHFR-TS) is an established antifolate target whose resistance-associated variants motivate ligand-directed discovery. This study combined molecular mechanics, Poisson-Boltzmann-based energy calculations, quantitative structure-activity relationship (QSAR) modelling, pharmacophore screening, in silico ADME prediction, and molecular dynamics to prioritise aminoquinoline-pyrimidine (AQPy) analogues. Twenty-three published AQPy compounds with whole-parasite antiplasmodial IC50 values were divided into a training set of 19 compounds and an external validation set of four compounds. Docking was based on the quadruple-mutant PfDHFR-TS structure (PDB 1J3K). The free-energy descriptor model showed a training-set coefficient of determination of approximately 0.96 and a four-compound external pIC50 root-mean-square error of approximately 0.23. A pharmacophore-guided design space produced 37 screened records corresponding to 33 distinct displayed compound identifiers. The most favourable modelled complexation-energy descriptors were associated with 15-106, 15-104, and 24-1. Calculated ADME descriptors and 200 ns molecular dynamics trajectories provided complementary information about the proposed binding poses and dynamic behaviour. Together, these results identify structural candidates for biochemical target testing and parasite-growth assays, while distinguishing the molecular-model rankings from experimentally measured inhibitory activity.
No takes yet. Share an insight, caveat, or question.
Souleymane et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: